Pyzchiva Injection, Solution
NDC Package 83457-652-01
Package Information
Pyzchiva (ustekinumab-ttwe) injection is ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative colitis). This formulation utilizes a injection, solution delivery system. Marketed by Cordavis Limited, this product is identified by NDC 83457-652 and is authorized under FDA application BLA761373.
Identification & Billing
- RxCUI: 2705568 - ustekinumab-ttwe 45 MG in 0.5 ML Prefilled Syringe
- RxCUI: 2705568 - 0.5 ML ustekinumab-ttwe 90 MG/ML Prefilled Syringe
- RxCUI: 2705568 - ustekinumab-ttwe 45 MG per 0.5 ML Prefilled Syringe
- RxCUI: 2705573 - Pyzchiva 45 MG in 0.5 ML Prefilled Syringe
- RxCUI: 2705573 - 0.5 ML ustekinumab-ttwe 90 MG/ML Prefilled Syringe [Pyzchiva]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 83457 - Cordavis Limited
- 83457-652 - Pyzchiva
- 83457-652-01 - 1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE
- 83457-652 - Pyzchiva
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (83457-652). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83457-652-01 identifies a specific commercial package of 1 syringe in 1 carton / 1 ml in 1 syringe of Pyzchiva, a human prescription drug labeled by Cordavis Limited. This injection, solution is formulated for subcutaneous use and contains ustekinumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cordavis Limited on May 01, 2025. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative colitis). It works by blocking certain natural proteins in your body (interleukin-12 and interleukin-23) that cause inflammation (swelling) in these conditions. Ustekinumab does not cure these diseases, but helps to lessen symptoms of the disease. It can help to decrease the amount of plaques in plaque psoriasis, decrease the number of swollen/painful joints in psoriatic arthritis, and decrease symptoms such as abdominal pain/cramping and diarrhea in Crohn's disease and ulcerative colitis.
How is this Cordavis Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83457065201. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
